Claims for Patent: 8,080,516

Summary for Patent: 8,080,516

Title:	Long lasting synthetic exendin-4 peptide conjugates
Abstract:	Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
Inventor(s):	Bridon; Dominique P. (San Francisco, CA), L\'Archeveque; Benoit (Dorval, CA), Holmes; Darren L. (Anaheim, CA), LeBlanc; Anouk (Montreal, CA), St. Pierre; Serge (Ile Bezard, CA)
Assignee:	Conjuchem, LLC (Los Angeles, CA)
Application Number:	11/170,967
Patent Claims:	1. A compound according to the following formula: ##STR00018## 2. A pharmaceutical composition comprising a compound according to the following formula: ##STR00019## in association with a physiologically acceptable medium. 3. A method of making a conjugate comprising the step of reacting a compound according to the following formula: ##STR00020## with albumin to form a covalent bond therebetween. 4. The method of claim 3, wherein said reacting occurs between a compound according to the following formula: ##STR00021## and cysteine 34 thiol of albumin. 5. The method of claim 2, wherein the reacting step occurs in vivo. 6. The method of claim 3, wherein the reacting step occurs ex vivo. 7. The method of claim 3, wherein the albumin is human serum albumin. 8. The conjugate produced by the method of claim 3. 9. The conjugate produced by the method of claim 4. 10. The conjugate produced by the method of claim 7. 11. A pharmaceutical composition comprising the conjugate of claim 8 in association with a physiologically acceptable medium. 12. A pharmaceutical composition comprising the conjugate of claim 9 in association with a physiologically acceptable medium. 13. A pharmaceutical composition comprising the conjugate of claim 10 in association with a physiologically acceptable medium. 14. The method of claim 4, wherein the albumin is serum albumin. 15. The method of claim 14, wherein the reacting step occurs ex vivo. 16. The method of claim 4, wherein the albumin is human serum albumin. 17. The method of claim 16, wherein the reacting step occurs ex vivo. 18. The conjugate produced by claim 15. 19. The conjugate produced by claim 15. 20. The conjugate produced by claim 17. 21. A pharmaceutical composition comprising the conjugate of claim 18 in association with a physiologically acceptable medium. 22. A pharmaceutical composition comprising the conjugate of claim 19 in association with a physiologically acceptable medium. 23. A pharmaceutical composition comprising the conjugate of claim 20 in association with a physiologically acceptable medium.

Details for Patent 8,080,516

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2019-05-17
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2019-05-17
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2019-05-17
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2019-05-17
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2019-05-17